News
13m
Zacks Small Cap Research on MSNARWR: Multiple Value Drivers for Long-Term Growth…ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has a robust pipeline ...
- First ASXL1 Pediatric Acute Myeloid Leukemia (AML) Patient Dosed at MD Anderson Cancer Center: Program Supported by Rare Pediatric Disease Designation (RPDD) ...
A low dose combination hormonal patch was found to be effective for pregnancy prevention based on results from a phase 3 study.
On Thursday, 2637 stocks advanced, 1327 declined and 151 remained unchanged on Bombay Stock Exchange with advance decline ...
Lupin receives US FDA approval for rivaroxaban tablets USP, 10 mg, 15 mg & 20 mg: Our Bureau, Mumbai Thursday, May 15, 2025, 15:40 Hrs [IST] Global pharma major Lupin Limited (Lup ...
Vadodara: Alembic Pharmaceuticals Limited has announced that it has received final approval from the US Food & Drug ...
Merck (MRK) stock in focus as the FDA approves its anticancer agent Welireg for two rare neuroendocrine tumors, expanding its ...
Montana just passed a new bill backed by longevity enthusiasts that will enable access to drugs and therapies that are not ...
MPox is endemic in DRC, and has continued to cause large numbers of cases in the WHO African Region. In April, 2025, the WHO has restated that MPox continues to be a Public Health Emergency of ...
1d
Sportschosun on MSNThe average time required to register an innovative new drug health insurance is 608 days...More than twice the number of Germany and JapanIt was pointed out that it takes a long time to apply health insurance for innovative new drugs in Korea. This is the result ...
Caliway has completed the End-of-Phase 2 (EOP2) meeting with the U.S. FDA for CBL-514, the world's first investigational drug for large-area subcutaneous fat reduction developed under the 505(b)(1) ...
Cytokinetics' PDUFA date for aficamten was extended to December 26th of 2025, due to the FDA's need to review a submitted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results